Tony Robbins’ and Peter Diamandis’ longevity company Fountain Life raises $18M

Fountain Life, a cutting-edge longevity healthcare company co-founded by Tony Robbins and Peter Diamandis, has successfully raised $18 million in a Series B funding round led by EOS Ventures. This funding round saw strong participation from existing board members and investors, bringing the company's total capital raised to approximately $108 million. The journey of Fountain Life began with Dr. William Kapp, an orthopedic surgeon whose passion for healthcare innovation was ignited at a medical conference eight years ago. He transitioned from private practice to co-founding a company that developed critical care hospitals. At a pivotal conference hosted by Dr. Daniel Kraft, Kapp discovered emerging technologies in genomics and microbiomics that inspired him to establish the Longevity Performance Center in Naples, Florida. In March 2020, Kapp's center caught the attention of Robbins and Diamandis, who were exploring synergies with their existing stem cell startup, Fountain Therapeutics. This collaboration quickly evolved into a merger, resulting in the formation of Fountain Life, with Kapp serving as CEO and both Robbins and Diamandis taking on co-founder and board member roles. Fountain Life operates four centers today, focusing on preventive health screenings to identify chronic conditions at their earliest stages. Their approach involves comprehensive testing that measures over 100 health biomarkers, including liver fat and microbiome concentrations. Kapp emphasizes three core principles of longevity: preventing avoidable deaths, optimizing health markers through scientifically validated treatments, and utilizing the latest regenerative therapies currently undergoing FDA trials. The company has seen notable success stories, including the early detection of kidney cancer in a patient through routine testing, leading to a successful treatment. The new funding will enable Fountain Life to expand its reach, with plans to open additional centers in Houston, Los Angeles, and Miami by 2026. While the subscription model is priced at $30,000 annually, with a $10,000 option for testing and AI support, Kapp is committed to making longevity healthcare more accessible. He aims to achieve this by training other medical facilities in Fountain’s methodologies, thereby driving down costs as technology and expertise become more widespread. As the field of longevity testing grows, Fountain Life is poised to be at the forefront of transforming how healthcare addresses aging and preventative care.